Greg Harrison
Stock Analyst at Scotiabank
(2.12)
# 2,703
Out of 4,834 analysts
88
Total ratings
39.71%
Success rate
-4.36%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Sector Outperform | $52 → $51 | $6.73 | +658.36% | 5 | May 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $41 → $26 | $14.01 | +85.65% | 6 | May 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $16.36 | +22.29% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.21 | +23.97% | 3 | May 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $450 → $442 | $434.38 | +1.75% | 6 | May 6, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $34 → $36 | $19.30 | +86.53% | 6 | May 5, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $74 → $71 | $28.26 | +151.24% | 5 | May 2, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $52 → $55 | $33.74 | +63.01% | 6 | Apr 30, 2025 | |
| UTHR United Therapeutics | Upgrades: Neutral | $314 | $303.92 | +3.32% | 2 | Apr 21, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $21.15 | +46.57% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $338 → $342 | $283.40 | +20.68% | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $17.25 | +131.88% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $47.09 | +59.27% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $60 | $21.33 | +181.29% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $5.72 | +214.69% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $7.17 | +206.83% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.40 | +975.27% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $8.08 | +1,026.93% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.63 | +24.61% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.45 | +233.33% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $15.36 | +153.91% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $3.95 | -24.05% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $3.14 | +2,129.30% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $29.36 | -72.75% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $20.12 | +168.39% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.68 | +782.35% | 5 | Mar 14, 2022 |
Rocket Pharmaceuticals
May 12, 2025
Maintains: Sector Outperform
Price Target: $52 → $51
Current: $6.73
Upside: +658.36%
Keros Therapeutics
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $14.01
Upside: +85.65%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $16.36
Upside: +22.29%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.21
Upside: +23.97%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $434.38
Upside: +1.75%
Liquidia
May 5, 2025
Maintains: Sector Outperform
Price Target: $34 → $36
Current: $19.30
Upside: +86.53%
Agios Pharmaceuticals
May 2, 2025
Maintains: Sector Outperform
Price Target: $74 → $71
Current: $28.26
Upside: +151.24%
BridgeBio Pharma
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $33.74
Upside: +63.01%
United Therapeutics
Apr 21, 2025
Upgrades: Neutral
Price Target: $314
Current: $303.92
Upside: +3.32%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $21.15
Upside: +46.57%
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $283.40
Upside: +20.68%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $17.25
Upside: +131.88%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $47.09
Upside: +59.27%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $21.33
Upside: +181.29%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $5.72
Upside: +214.69%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $7.17
Upside: +206.83%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.40
Upside: +975.27%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $8.08
Upside: +1,026.93%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.63
Upside: +24.61%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.45
Upside: +233.33%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $15.36
Upside: +153.91%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.95
Upside: -24.05%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $3.14
Upside: +2,129.30%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $29.36
Upside: -72.75%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $20.12
Upside: +168.39%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.68
Upside: +782.35%